Rubrofusarin 6-[glucosyl-(1->3)-glucosyl-(1->6)-glucoside]



Compound IDCDAMM01729
Common nameRubrofusarin 6-[glucosyl-(1->3)-glucosyl-(1->6)-glucoside]
IUPAC name6-[6-[[3,5-dihydroxy-6-(hydroxymethyl)-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-8-methoxy-2-methylbenzo[g]chromen-4-one
Molecular formulaC33H42O20

Experimental data

Retention time21.61
Adduct[M+Na]+
Actual mz781.222
Theoretical mz781.216
Error7.4
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.0068

Identifiers and class information

Inchi keyHLSFLOGWAMZXNK-UHFFFAOYNA-N
SmilesO=C1C=C(OC2=CC=3C=C(OC)C=C(OC4OC(COC5OC(CO)C(O)C(OC6OC(CO)C(O)C(O)C6O)C5O)C(O)C(O)C4O)C3C(O)=C12)C
SuperclassOrganic oxygen compounds
ClassOrganooxygen compounds

Pharmacokinetic properties

Number of descriptor values(#stars)12
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)21
Number of reactive functional groups (#rtvFG)3
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)758.683
Computed dipole moment(dipole)8.954
Total solvent accessible surface area (SASA)970.168
Hydrophobic component of SASA (FOSA)449.884
Hydrophilic component of SASA (FISA)387.116
Pie component of the SASA (PISA)133.169
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1954.25
Number of hydrogen bond donors (donorHB)10
Number of hydrogen bond acceptors (accptHB)29.25
Free energy of solvation of dipole (dip^2/V)0.0410247
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0953408
Globularity descriptor (glob)0.779181
Predicted polarizability in cubic angstroms (QPpolrz)59.843
Predicted hexadecane/gas partition coefficient (QPlogPC16)22.214
Predicted octanol/gas partition coefficient (QPlogPoct)51.667
Predicted water/gas partition coefficient (QPlogPw)44.417
Predicted octanol/water partition coefficient (QPlogPo/w)-3.493
Predicted aqueous solubility (QPlogS)-1.382
Conformation-independent predicted aqueous solubility (CIQPlogS)-3.495
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-5.74
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)2.113
Predicted brain/blood partition coefficient (QPlogBB)-4.953
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.635
Predicted skin permeability, log Kp (QPlogKp)-6.169
PM3 calculated ionization potential (IP(ev))8.287
PM3 calculated electron affinity (EA(eV))0.775
Number of likely metabolic reactions (#metab)13
Prediction of binding to human serum albumin (QPlogKhsa)-2.137
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)302.188
Number of nitrogen and oxygen atoms (#NandO)20
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
P60568IL2Interleukin-2T61698SEA
P17931LGALS3Galectin-3T72038SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
P14679TYRTyrosinaseT97035SEA
Q9GZQ4NMUR2Neuromedin-U receptor 2T04210SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
P05231IL6Interleukin-6T32578SEA
Q99417MYCBPMYCBP messenger RNAT37298SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T32578DI0028Anemia[ICD-11: 3A00-3A9Z]P05231IL6
T37298DI0235Liver cancer[ICD-11: 2C12]Q99417MYCBP
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025